294 related articles for article (PubMed ID: 28160562)
1. The tumor suppressor capability of p53 is dependent on non-muscle myosin IIA function in head and neck cancer.
Coaxum SD; Tiedeken J; Garrett-Mayer E; Myers J; Rosenzweig SA; Neskey DM
Oncotarget; 2017 Apr; 8(14):22991-23007. PubMed ID: 28160562
[TBL] [Abstract][Full Text] [Related]
2. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk
Tanaka N; Patel AA; Tang L; Silver NL; Lindemann A; Takahashi H; Jaksik R; Rao X; Kalu NN; Chen TC; Wang J; Frederick MJ; Johnson F; Gleber-Netto FO; Fu S; Kimmel M; Wang J; Hittelman WN; Pickering CR; Myers JN; Osman AA
Clin Cancer Res; 2017 Nov; 23(21):6541-6554. PubMed ID: 28790110
[No Abstract] [Full Text] [Related]
3. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of cancer-initiating cells stemness properties by abrogating S100A4 calcium binding ability in head and neck cancers.
Cheng LH; Hung KF; Huang TF; Hsieh HP; Wang SY; Huang CY; Lo JF
Oncotarget; 2016 Nov; 7(48):78946-78957. PubMed ID: 27793047
[TBL] [Abstract][Full Text] [Related]
5. Axon guidance molecule semaphorin3A is a novel tumor suppressor in head and neck squamous cell carcinoma.
Wang Z; Chen J; Zhang W; Zheng Y; Wang Z; Liu L; Wu H; Ye J; Zhang W; Qi B; Wu Y; Song X
Oncotarget; 2016 Feb; 7(5):6048-62. PubMed ID: 26755661
[TBL] [Abstract][Full Text] [Related]
6. The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex.
Verduci L; Ferraiuolo M; Sacconi A; Ganci F; Vitale J; Colombo T; Paci P; Strano S; Macino G; Rajewsky N; Blandino G
Genome Biol; 2017 Dec; 18(1):237. PubMed ID: 29262850
[TBL] [Abstract][Full Text] [Related]
7. [Association of the expression of p53 and p16INK4A with the clinical and morphological characteristicsof patients with head and neck squamous cell cancer].
Stukan AI; Chukhray OY; Porkhanov VA; Bodnya VN
Arkh Patol; 2019; 81(3):12-18. PubMed ID: 31317926
[TBL] [Abstract][Full Text] [Related]
8. Survival of Head and Neck Cancer Cells Relies upon LZK Kinase-Mediated Stabilization of Mutant p53.
Edwards ZC; Trotter EW; Torres-Ayuso P; Chapman P; Wood HM; Nyswaner K; Brognard J
Cancer Res; 2017 Sep; 77(18):4961-4972. PubMed ID: 28760853
[TBL] [Abstract][Full Text] [Related]
9. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of TP53 mutation-associated microRNA-182 promotes tumor cell proliferation and migration in head and neck squamous cell carcinoma.
Wang L; Jiang H; Li W; Jia C; Zhang H; Sun Y; Chen X; Song X
Arch Oral Biol; 2017 Jan; 73():105-112. PubMed ID: 27744260
[TBL] [Abstract][Full Text] [Related]
11. Passenger strand of miR-145-3p acts as a tumor-suppressor by targeting MYO1B in head and neck squamous cell carcinoma.
Yamada Y; Koshizuka K; Hanazawa T; Kikkawa N; Okato A; Idichi T; Arai T; Sugawara S; Katada K; Okamoto Y; Seki N
Int J Oncol; 2018 Jan; 52(1):166-178. PubMed ID: 29115582
[TBL] [Abstract][Full Text] [Related]
12. Allele-specific silencing of mutant p53 attenuates dominant-negative and gain-of-function activities.
Iyer SV; Parrales A; Begani P; Narkar A; Adhikari AS; Martinez LA; Iwakuma T
Oncotarget; 2016 Feb; 7(5):5401-15. PubMed ID: 26700961
[TBL] [Abstract][Full Text] [Related]
13. Specific TP53 mutations predict aggressive phenotype in head and neck squamous cell carcinoma: a retrospective archival study.
Peltonen JK; Vähäkangas KH; Helppi HM; Bloigu R; Pääkkö P; Turpeenniemi-Hujanen T
Head Neck Oncol; 2011 Apr; 3():20. PubMed ID: 21513535
[TBL] [Abstract][Full Text] [Related]
14. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of junctional adhesion molecule-A via p63/GATA-3 in head and neck squamous cell carcinoma.
Kakuki T; Kurose M; Takano K; Kondoh A; Obata K; Nomura K; Miyata R; Kaneko Y; Konno T; Takahashi S; Hatakeyama T; Kohno T; Himi T; Kojima T
Oncotarget; 2016 Jun; 7(23):33887-900. PubMed ID: 27036044
[TBL] [Abstract][Full Text] [Related]
16. The p53 molecule and its prognostic role in squamous cell carcinomas of the head and neck.
Nylander K; Dabelsteen E; Hall PA
J Oral Pathol Med; 2000 Oct; 29(9):413-25. PubMed ID: 11016683
[TBL] [Abstract][Full Text] [Related]
17. TP53 Mutations in Head and Neck Squamous Cell Carcinoma and Their Impact on Disease Progression and Treatment Response.
Zhou G; Liu Z; Myers JN
J Cell Biochem; 2016 Dec; 117(12):2682-2692. PubMed ID: 27166782
[TBL] [Abstract][Full Text] [Related]
18. Disruptive TP53 mutation is associated with aggressive disease characteristics in an orthotopic murine model of oral tongue cancer.
Sano D; Xie TX; Ow TJ; Zhao M; Pickering CR; Zhou G; Sandulache VC; Wheeler DA; Gibbs RA; Caulin C; Myers JN
Clin Cancer Res; 2011 Nov; 17(21):6658-70. PubMed ID: 21903770
[TBL] [Abstract][Full Text] [Related]
19. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
20. Evolutionary Action Score of TP53 Identifies High-Risk Mutations Associated with Decreased Survival and Increased Distant Metastases in Head and Neck Cancer.
Neskey DM; Osman AA; Ow TJ; Katsonis P; McDonald T; Hicks SC; Hsu TK; Pickering CR; Ward A; Patel A; Yordy JS; Skinner HD; Giri U; Sano D; Story MD; Beadle BM; El-Naggar AK; Kies MS; William WN; Caulin C; Frederick M; Kimmel M; Myers JN; Lichtarge O
Cancer Res; 2015 Apr; 75(7):1527-36. PubMed ID: 25634208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
